Login
Navigate Fool.com
Will CTIC beat
the market?
Community Rating: 1 Star: Ominous

3.07 0.08 (2.68%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $3.04
Previous Close $2.99
Daily Range $3.01 - $3.20
52-Week Range $0.97 - $4.25
Market Cap $459.4M
P/E Ratio -7.14
Dividend (Yield) $0.00 (0.0%)
Volume 2,692,526
Average Daily Volume 4,643,142
Current FY EPS -$0.36

How do you think CTIC
will perform against the market?

Top CTIC Bull/Bear Pitches

 

dbbfool63 (< 20)
Submitted August 27, 2009

Good entry point for mid to long term. I couldn't get in until it got above a dollar to rate it although been watching since .o7/shr. Probably could of got in lower, but lost track watching others.

0 Replies Reply Report this Post
 

kanstockman (0)
Submitted June 11, 2007

2008 a drug in Phase III stage II should be on the market with a half a billion in sales by the 2nd Q. Right now the stock is being dragged down by the sector componants.

2 Replies Reply Report this Post

News & Commentary Rss Feed

What's Next for Geron and Imetelstat?

A closer look at the promise and peril of Geron's imetelstat and the author's expectation of the most likely outcome from its current clinical hold.

Today's Biggest Biotech Stories: Roche, Regeneron, Cell Therapeutics, and AstraZeneca

Roche, Regeneron, Cell Therapeutics, and AstraZeneca could all make health-care headlines this morning. Here's why.

Can You Still Ride This Month's 3 Biggest Winners To Greater Gains?

Biotech dominates in January as Intercept, Cell Therapeutics, and Neurocrine all surge after good drug-trial news.

3 Stocks to Get on Your Watchlist

A big-box retail giant, an up-and-coming developer of a tardive dyskinesia treatment, and a short-sale candidate.

Healthcare Stocks Up Just Before Bell; Cell Therapeutics Outlines Plans for New Cancer Drug

Sector Update: Healthcare

3 Humongous Health-Care Stocks This Week

Therapeutics ruled the world of health-care this week -- with Chelsea, PTC, and Stemline coming out on top and Sarepta and Cell not far behind.

Why NII Holdings, Pacific Biosciences of California, and Cell Therapeutics Are Today's 3 Best Stocks

The S&P 500 dips on weaker economic data as NII Holdings, Pacific Biosciences of California, and Cell Therapeutics gallop higher by double-digits.

Sector Update: Healthcare Shares Flat Pre-Market; Cell Therapeutics Soars 13% on Acquiring Rights to

Sector Update: Healthcare Shares Flat Pre-Market; Cell Therapeutics Soars 13% on Acquiring Rights to 2 Anti-Cancer Compounds

This Week in Biotech: The FDA, NICE, and DOJ Weigh In

In part two of This Week in Biotech, we examine a mix of six companies impacted by regulatory approval and enforcement agencies this past week.

See More CTIC News...

Sector

Healthcare

Industry

Drugs

Cell Therapeutics, Inc. (CTIC) Description

The Company develops, acquires and commercializes novel treatments for cancer and focuses its research and in-licensing activities on identifying and developing new, less toxic and effective ways to treat cancer. Website: http://www.celltherapeutics.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks